The Top 5 Biosimilars Articles for the Week of January 21

January 25, 2019

The Center for Biosimilars® recaps the top news for the week of January 21, 2019.

Transcript:

Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of January 21.

Number 5: A recent study found that the increased use of infliximab biosimilars corresponded to increased reporting of adverse events.

Number 4: Number 4: At the CBI 14th Biosimilars Summit, representatives of employer groups discussed the role that businesses have in promoting biosimilar awareness.

Number 3: In 2018, a Canadian payer launched its pilot Biosimilar Transition Program. Now that the pilot is complete, the payer is calling the program a success.

Number 2: Sandoz’s biosimilar etanercept, Erelzi, was granted an indication for the treatment of psoriatic arthritis by Health Canada.

Number 1: Last week, the FDA approved the third trastuzumab biosimilar, Ontruzant.

Finally, last week, our e-newsletter asked if the less frequent dosing schedule of Alexion’s ravulizumab will be enough to keep biosimilar eculizumab from achieving high uptake.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.